Plus   Neg

Amgen: GALACTIC-HF Trial Meets Primary Composite Endpoint; Fails To Meet Secondary Endpoint

Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier announced topline results from GALACTIC-HF, a phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction. The company said the results of GALACTIC-HF showed that treatment with omecamtiv mecarbil achieved the primary composite efficacy endpoint and demonstrated a statistically significant effect to reduce cardiovascular death or heart failure events compared to placebo. No reduction in the secondary endpoint of cardiovascular death was observed in the trial.

The results from GALACTIC-HF will be presented at the American Heart Association Scientific Sessions 2020, in a virtual Late Breaking Clinical Trial session on November 13.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT